Oncopeptides AB's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 88.62.
Oncopeptides AB's Days Inventory for the
three
months ended in Mar. 2026 was 2503.29.
Oncopeptides AB's Days Payable for the
three
months ended in Mar. 2026 was 1954.27.
Therefore, Oncopeptides AB's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 637.64.
Oncopeptides AB (FRA:OND) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Oncopeptides AB Cash Conversion Cycle Related Terms
Oncopeptides AB Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Oncopeptides AB's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OND vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Oncopeptides AB's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Oncopeptides AB's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncopeptides AB (FRA:OND) has a Cash Conversion Cycle of 637.64 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Oncopeptides AB and its competitors.
Is Oncopeptides AB's Cash Conversion Cycle too high?
Oncopeptides AB's current Cash Conversion Cycle is 637.64. The Biotechnology industry median Cash Conversion Cycle is 102.77. Oncopeptides AB's value of 637.64 is 520.5% above this industry median. Overall, Oncopeptides AB has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's Cash Conversion Cycle compare to VRTX and REGN?
Oncopeptides AB's Cash Conversion Cycle of 637.64 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 102.77. Oncopeptides AB's value of 637.64 is 520.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 102.77, based on 872 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncopeptides AB's current Cash Conversion Cycle of 637.64 is 520.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Oncopeptides AB and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 102.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncopeptides AB's current Cash Conversion Cycle is 637.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.36, compared to a current price of €0.14 — trading 61.7% below its estimated fair value. The current Cash Conversion Cycle is 637.64 and 520.5% above the Biotechnology industry median of 102.77. Oncopeptides AB's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current Cash Conversion Cycle is 637.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (FRA:OND) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of €0.14 is trading 61.7% below its estimated GF Value™ of €0.36.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for FRA:OND:
Cash Conversion Cycle: 637.64
GF Value™: €0.36 vs. price of €0.14 (61.7% below fair value)
Industry Position: 520.5% above the Biotechnology median
No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
36GF Score
Get the complete analysis for FRA:OND
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OND has been successfully added to your 
